Physician profile
Chen Tang
NPI 1679960264
$3,975.13
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $403 · 2023: $2,894 · 2024: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.53 | 2022-2024 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $690.35 | 2022-2024 | Cimzia |
| Amgen INC. | $474.25 | 2022-2024 | Enbrel, Tavneos, Prolia |
| Novartis Pharmaceuticals Corporation | $360.64 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $243.57 | 2022-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $155.14 | 2023 | Saphnelo |
| Ani Pharmaceuticals, INC. | $151.28 | 2023 | Purified Cortrophin Gel |
| Organon LLC | $149.21 | 2023-2024 | Hadlima |
| Janssen Biotech, INC. | $139.89 | 2022-2023 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $124.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $112.88 | 2024 | Libtayo |
| Octapharma USA, INC. | $95.98 | 2023 | Octagam Immune Globulin (Human) |
| Viiv Healthcare Company | $92.77 | 2022-2023 | Apretude, Cabenuva, Rukobia |
| Radius Health, INC. | $90.81 | 2023-2024 | Tymlos |
| Shionogi INC | $69.15 | 2022-2023 | Fetroja |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.69 | 2023 | Dificid, Pifeltro, Delstrigo |
| Kyowa Kirin, INC. | $35.23 | 2023 | Crysvita |
| Fresenius Kabi USA, LLC | $34.41 | 2023 | Idacio |
| Genzyme Corporation | $31.24 | 2023 | |
| Lilly USA, LLC | $29.93 | 2023-2024 | Taltz |
| Kiniksa Pharmaceuticals International, Plc | $20.03 | 2024 | Arcalyst |
| Pfizer INC. | $18.56 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.40 | 2022 | |
| Glaxosmithkline, LLC. | $15.30 | 2023 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2023 | Hyqvia |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2023 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.